Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Better Buy: Ocugen vs. Pfizer

Ocugen: Potential for major gains
Adria Cimino $Ocugen (OCGN.US)$ : Ocugen surged more than 700% in a matter of weeks earlier this year on optimism about potential coronavirus vaccine sales. The biotech company partnered with Bharat Biotech to co-commercialize that company's vaccine -- Covaxin -- in the U.S. The deal later expanded to include Canada. But Ocugen has struggled to actually bring Covaxin to market. As a result, shares have dropped 68% from their peak back in February.

Pfizer: Something to attract nearly every investor
Keith Speights $Pfizer (PFE.US)$ : If you're an income-seeking investor, Pfizer is a no-brainer choice over Ocugen. The big drugmaker's dividend currently yields 2.7%. It's a pretty safe bet that Pfizer will increase its dividends for years to come. Ocugen, of course, doesn't make enough money to pay a dividend.

Ocugen or Pfizer?
Your choice may depend on your investing style. An investor looking for a chance at steep gains fast may go for Ocugen. But as Keith says, the risk is that such a stock also may suffer big losses. Overall, Pfizer represents an opportunity to grow your investment over time -- and expose yourself to a lot less risk. In general, that's always a better recipe for long-term investing success.

Part of the content is taken from The Motley Fool.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
1
1
17
+0
1
Translate
Report
65K Views
Comment
Sign in to post a comment